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Background: Acetylsalicylic acid is one of the most used analgesics to treat an acute migraine attack. Next to the
inhibitory effects on peripheral prostaglandin synthesis, central mechanisms of action have also been discussed.
Methods: Using a standardized model for trigeminal-nociceptive stimulation during fMRI scanning, we investigated
the effect of acetylsalicylic acid on acute pain compared to saline in 22 healthy volunteers in a double-blind
within-subject design. Painful stimulation was applied using gaseous ammonia and presented in a pseudo-randomized
order with several control stimuli. All participants were instructed to rate the intensity and unpleasantness of
every stimulus on a VAS scale. Based on previous results, we hypothesized to find an effect of ASA on central pain
processing structures like the ACC, SI and SII as well as the trigeminal nuclei and the hypothalamus.
Results: Even though we did not find any differences in pain ratings between saline and ASA, we observed decreased
BOLD signal changes in response to trigemino-nociceptive stimulation in the ACC and SII after administration of ASA
compared to saline. This finding is in line with earlier imaging results investigating the effect of ASA on acute pain.
Contrary to earlier findings from animal studies, we could not find an effect of ASA on the trigeminal nuclei in the
brainstem or within the hypothalamic area.
Conclusion: Taken together our study replicates earlier findings of an attenuating effect of ASA on pain processing
structures, which adds further evidence to a possibly central mechanism of action of ASA.
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Acetylsalicylic acid (ASA), corresponding to the group
of non-steroidal anti-inflammatory drugs (NSAIDs), is
until today one of the most frequently used analgesics
for pain syndromes and widely applied in the treatment
of headache. The efficiency of 500-1000 mg ASA admin-
istration in the treatment of acute migraine attack has
been proven in several clinical trials [1-3] and there are
also studies showing a prophylactic effect of ASA on mi-
graine without aura [4]. In 1971 its inhibitory effect on
local prostaglandine synthesis was discovered [5,6]. This
mechanism of action is mainly driven by its inhibitory
effect on the enzyme cyclooxygenase which is subdivided
into two isoenzymes cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2) [7-10]. Because traditional
NSAIDs like Acetylsalicylic acid inhibit both COX-1 and* Correspondence: a.may@uke.de
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in any medium, provided the original work is pCOX-2 isoenzymes, which may lead to adverse gastric
side effects, more specific COX-2 inhibitors have been
introduced [11,12]. Both isoenzymes are expressed in
peripheral tissues and the central nervous system (CNS)
(for review see [7]) and although a solely peripheral
mechanism of action was suggested for several years,
various studies suggested an additional central effect of
ASA [13-20]. Hence, next to the inhibition of peripheral
prostaglandine synthesis, a central mechanism, respect-
ively the interaction of both, is the most likely mode of
action [15,21]. In the acute migraine attack ASA could
also be shown to attenuate accompanying symptoms like
nausea or photophobia [22,23], again suggesting central
nervous effects. In addition ASA exhibits an inhibitory
effect on the activation of central trigeminal neurons
after sagittal sinus stimulation [19,24]. Moreover, a high
binding affinity of ASA to the dorsal horn and nuclei in
the brainstem could be observed [19]. Conversely, a very
early study by Shyu & Lin explored a possible effect ofis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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finding a significantly elevated pain threshold after ASA
administration into the anterior hypothalamic area but
not after injection of ASA into the periaqueductual grey
matter or dorsal raphe region [14]. As this effect could
be blocked by prestimulus blockade of serotonin recep-
tors within the hypothalamic regions, the authors sug-
gested a central serotonergic mechanism of action for
ASA within this area [14]. The involvement of serotonin
receptors in the analgesic effect of ASA has also been
proposed by other studies [25].
Recently, using fMRI the neuronal correlates of an-
algesic (acute pain) and antihyperalgesic (mechanical
hyperalgesia) conditions were investigated and pharmaco-
logically modulated using a nonselective COX-inhibitor
(ASA) and a selective COX-2 inhibitor (parecoxib) [21,26].
Following ASA, a decreased activation of the primary (SI)
and secondary somatosensory cortex (SII) [21] and a
slight decrease in the anterior cingulate cortex [26] could
be revealed in the acute pain model. These effects were
stronger in the hyperalgesic model, where a stronger
activation for placebo compared to ASA was found in
several brain areas including SI, bilateral SII, insula, mid-
dle and inferior frontal cortices as well as the parietal
association cortex [21].
Based on these results we investigated the influence of
500 mg ASA (i.v.) on trigemino-nociceptive stimulation
using a previously described standardized design for
functional magnetic resonance imaging (fMRI) [27]. As
trigeminal-nociceptive stimulation causes acute pain,
we mainly hypothesized to find an effect of ASA on SI,
SII or the anterior cingulate cortex as reported earlier
[21,26] and additionally investigated a possible effect of
ASA on neuronal activation in the hypothalamus and
the trigeminal nuclei [14,24].
Methods
Subjects
We used fMRI to investigate 22 healthy subjects in
a randomized, double-blind, placebo-controlled, cross-
over study. All participants were devoid of migraine his-
tory or any other neurological, internal or psychiatric
disorder. Participants were also controlled for having
any history of pain syndrome, as well as acute minor
pain (e.g. tooth-ache) and possible contraindication for
ASA. None of the volunteers took any type of medica-
tion. Participants not fitting these criteria were not in-
cluded. Prior to fMRI data acquisition, all volunteers
were informed in detail about the purpose of the study
and the possibility to withdrawal from the experiment at
any time. Remuneration was paid for study participation.
The study was approved by the local Ethics Committee
and conducted in accordance to the declaration of
Helsinki.Study design
All participants underwent two separate fMRI sessions
whereof the second fMRI scan was conducted at least
8-14 days after the first session to control for wash-
out effects. Prior to the first fMRI scan, all participants
underwent a training session outside the scanner to
get used to the study paradigm which is a slightly
extended version of a successfully used experiment
described in detail elsewhere [27]. In a nutshell, dur-
ing the fMRI scan all volunteers received 15 stan-
dardized trigemino-nociceptive stimuli (gaseous ammonia)
which were applied through a thin Teflon tube (connected
to the olfactometer outside of the scanner) into the
left nostril of the participants. Furthermore, volunteers
perceived several control stimuli during the event-
related fMRI consisting of olfactory (rose odor) as well as
an odorless (air puffs) stimulation and a visual stimu-
lus (flickering checkerboard). The latter being, in con-
trast to the intranasal applied stimuli, presented on
the screen in front of the participants for 4 seconds.
Presentation of the stimuli took place in a pseudo-
randomized order, in order to control for trigeminal
stimuli not to be followed by each other. Subsequently,
all subjects had to rate the intensity (from 0 (no pain/
no sensation to 100 (highest pain imaginable/highest
intensity imaginable)) and pleasantness (from -50 very
pleasant to 50 very unpleasant) of the stimulus on a
visual analog scale (VAS). Preceding the next run, an
inter-trial interval (ITI) of 4-6 seconds followed. All
volunteers were instructed to breath orally throughout
the entire experiment.
Medication (ASA)
The intravenous administration of 500 mg ASA or saline
(0.9%) was assigned in a randomized order between par-
ticipants. Thus, half of the subjects received saline dur-
ing the first fMRI data acquisition whereas the second
half of the volunteers received the medication during the
first fMRI data acquisition. Consequential, after a wash-
out phase of 8-14 days the correspondent substance
(verum or saline) was administered before the second
fMRI session. The study was conducted under double-
blind conditions, i.e. the administration of the drug was
randomized and done by an independent doctor. ASA
was administered approx. 15 minutes (14-17 minutes)
prior to scanning. This time window was chosen because
it could be shown earlier that while the first exponent of
ASA has a half-life of 2.8 minutes, the second exponent
of ASA has a half-life of 15 minutes [28]. Because the
cyclooxygenase inhibition of ASA is irreversible, Cmax of
ASA does not play such a crucial role for our study and
since SA has a very long half life time of up to 4 hours,
we can be sure that the effect lasts for the duration of
our study.
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Anatomical and functional data were collected using a 3
T Scanner (Siemens-Trio) with a 32 channel head coil.
The protocol included a high resolution T1-weighted
structural image (voxel size 1×1×1 mm) for every par-
ticipant using a Magnetization Prepared Rapid Gradient
Echo (MPRAGE) sequence as well as T2*-weighted im-
ages using an echo-planar imaging sequence in an axial
order (Time of Repetition: 2.62 s, echo time: 30 ms, flip
angle 80°, field of view: 220×220 mm, 40 axial slices, slice
thickness 2 mm, gap of 1 mm). Every session consisted of
855-1202 volumes (mean 965.7 volumes). Differences in
volumes acquired were due to time differences within
the rating procedure of the subjects. The fMRI proto-
col was an event-related design. Because of our spe-
cial interest in the brainstem we chose the caudal part
of the cerebellum in each subject for use as a point of
reference to the lowest slice which also refers to an
earlier study [27].
Behavioral data analysis
All analyses regarding behavioral data were performed
using SPSS (Statistical Program for Social Sciences;
Version 22.0). We calculated averaged pain ratings
subsequent to trigemino-nociceptive stimulation for every
subject in every session. A paired t-tests was per-
formed to compare pain intensity ratings between ses-
sions (medication vs. saline) using a statistical threshold
of p < 0.05.
Statistical analysis for imaging data
Imaging data was processed and analyzed using statis-
tical parametric mapping (SPM8; Wellcome Department
for Imaging Neuroscience, London, UK). Individual
functional scans were preprocessed including the follow-
ing steps: slice time correction, data realignment of
all volumes to the first volume, co-registration and
normalization into the MNI (Montreal Neurological
Institute) stereotactical space as well as smoothing using
an isotropic 8 mm full-width at half-maximum (FWHM)
three- dimensional Gaussian kernel. Thereafter, statis-
tical analyses on a single subject level were performed
using a general linear model (GLM). The different
events “Ammonia” (trigemino-nociceptive stimulation),
“rose odor”, “air puffs”, “visual stimulation” and “button
presses” were therefore modeled as delta functions con-
volved with the default SPM8 canonical hemodynamic
response function. Additionally six movement parame-
ters (translation and rotation around x-, y-, and z-axis)
were included in the 1st-level design matrix of every sub-
ject as regressors of no interest. As the major interest of
our study concerned the different effect of medication
or saline on painful stimulation, contrast images for every
subject were generated to identify regions showingincreased activation during painful stimulation compared
to air puffs in medication vs. saline conditions [Saline
session (“ammonia > air puffs”) > Medication session
(“ammonia > air puffs”)]. A t-statistic was calculated for
every voxel and contrast images were inserted into a ran-
dom effects second level model (one-sample t-test) for
group analyses. This was conducted to assess BOLD sig-
nal differences in response to painful stimulation be-
tween medication and saline condition. Assuming that
ASA could have a central effect on pain related structures
as the anterior cingulate cortex, SI or SII as indicated by
earlier studies [21,26], we were especially interested in
the responses of these regions to trigeminal-nociceptive
stimulation. Therefore, we conducted small volume cor-
rection using family wise error correction (FWE p<0.05)
for the anterior cingulate cortex, SI and SII. Specifically,
we set the threshold to p <0.05 FWE corrected for the
anterior cingulate using a mask of the right and left
anterior cingulate cortex from the Harvard-Oxford
cortical/subcortical structural atlas (http://www.cma.
mgh.harvard.edu/fsl_atlas.html). For regions of interest
that are not explicitly defined in the Harvard-Oxford
cortical/subcortical structural atlas (SI, SII) small volume
corrections (FWE-corrected, p < 0.05) were performed
using 16 mm spheres centered on coordinates [x = ±52,
y = -26, z = 18] for SII and [x = ± 36, y = -30, z = 54]
for SI taken from prior research [21,26] after converting
them from Talairach in MNI space . As previous animal
studies found an effect of ASA on the anterior hypo-
thalamic area and the trigeminal nuclei, we again
performed small volume corrections (FWE-corrected,
p < 0.05) using a 6 mm radius sphere for the trigeminal nu-
clei centered on coordinates [x = 6, y = -39, z = -45; x = -9,
y = -39, z = -45] of a previous study [29] adjusted to the
setting of our scanner ( left : x = -10, y = -40, z = -46;
right: x = 6, y = -40, z = -46). For the hypothalamus we
also used a sphere of 12 mm radius centered on coordi-
nates [x = 0, y = -2, z = -8] as reported in the Talairach
atlas and used in previous studies [30] after converting
them in MNI space.
Results
Two subjects had to be excluded from data analysis be-
cause they did not show a clear painful response to
trigemino-nociceptive stimulation (mean pain rating in
both sessions <35). One participant withdrew from the
study. Therefore, our data analysis (behavioral as well as
fMRI data) is restricted to 19 healthy subjects.
Behavioral data
Mean Pain intensity rating (±SEM) for the ASA session
was 61.7 ± 2.73 and for the saline session 62.1 ± 2.71. A
paired t-test comparing the average pain ratings of both
sessions failed to reach significance (p > 0.05).
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Main effects of painful trigeminal stimulation
Pooling both sessions together (medication and saline
session) we replicated earlier findings (of studies using
the same paradigm) [27,29,31] of a statistically signifi-
cant increase in neuronal activation in several pain
related cortical and subcortical brain areas following
trigemino-nociceptive stimulation. This statistical signifi-
cant increase (FWE corrected) in BOLD signal changes
included the middle and anterior cingulate cortex, the
insular cortex, thalamus, the cerebellum as well as som-
atosensory cortices.
Effect of ASA on trigeminal stimulation compared
to Saline
As shown in Figure 1, we found an increased activation
in the left ACC [x = -6, y = 20, z = 32; T(18) = 4.13,
p = 0.029 (FWE corrected)) as well as in the right
SII [x = 54, y = -28, z = 4, T(18) = 4.4 p = 0.047
(FWE corrected)] regarding the contrast [Placebo
(Ammonia > air puffs) > ASS (Ammonia > air puffs)]
replicating the trend found in a previous study [26].
Contrary to earlier results, we did not reveal any sig-
nificant activation in SI (p > 0.05 (FWE corrected)).
Additionally, no increased activation for placebo com-
pared to ASA condition could be revealed regarding the
hypothalamic area or the trigeminal nuclei. No significant
differences could be revealed for the opposite contrast
(ASA > Saline).
Discussion
Finding a significantly decreased activation of ACC and
SII in response to trigeminal nociceptive stimulation in
the ASA condition compared to placebo (Figure 1), we
could replicate a trend shown in previous studies indi-
cating a possible central mechanism of ASA not only
on mechanically induced hyperalgesia but also on acuteFigure 1 BOLD signal intensity during painful stimulation: Saline > AS
and secondary somatosensory cortex (right) during nociceptive input (amm
Visualization threshold is set to p < 0.001 (uncorrected). Bold activation is p
T values of individual voxels.pain [21,26]. The ACC as well as SII are structures fre-
quently found during nociceptive stimulation and known
to play a crucial role in the processing of pain [32-36].
While the ACC has been attributed among others to
reflect an emotional pain component [37,38], it is also
crucially involved in antinociception and anticipatory
anxiety [39]. SII, also shown to be modulated by ASA, is
related to pain intensity coding [36] and seems to be
responsible for the integration of salient (painful and
nonpainful) somatosensory stimuli [40]. However, we
did not observe any behavioral effect of ASA on pain in-
tensity perception of the volunteer. This lack of a behav-
ioral effect combined with an obtained CNS effect of
ASA on painful stimulation is in line with an earlier
study using mechanical pain [21] and painful carbon di-
oxide pulses delivered to the nasal muscosa [17]. More
evidence for a central effect of ASA on pain processing
is coming from an imaging study investigating pain rat-
ings as well as stimulus evoked responses to nociceptive
stimulation using an electroencephalogram (EEG). In
this case, oral administration of 1000 mg ASA reduced
the overall pain ratings as well as all pain related cere-
bral potentials significantly [13]. Of note, effects of ASA
increased with time, meaning that ASA showed an at-
tenuating effect compared to placebo on all relevant
variables during the experiment. But this effect did not
reach significance before 90 minutes post medication
[13]. Additionally, a study using electrical brain poten-
tials could show an effect of ASA on late but not early
waveforms of the evoked potentials in healthy man,
which are suggested to reflect pain perception process-
ing [18]. Nonetheless, investigating a possible difference
between later and earlier VAS scores of ammonia, we
could not find a significant difference within the ASA
condition. However, as these earlier studies did not spe-
cifically investigate the effect of ASA on migraine, the
exact mechanism of action how ASA reduces head painA. Increased BOLD signal intensity in the anterior cingulate cortex (left)
onia > air puffs) after saline treatment compared to ASA condition.
rojected onto a MNI152_T1 brain template (FSL). Color scales show
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ation plays a pivotal role in migraine, several studies in-
vestigated the effect of ASA on trigeminovascular
nociceptive input [19,24]. Especially the use of an elec-
trophysiological animal model of superior sagittal sinus
stimulation [24] was promising to gain further insight in
the mechanisms of actions through which ASA exerts
its clinical effect in migraine, as it reflects migraine-like
pain or neuropeptide release similar to that in an acute
attack [41]. An inhibitory effect on the activation of cen-
tral brainstem nuclei [19] as well as reduced peak-to-
peak amplitudes for trigeminal somatosensory evoked
potentials in the dorsolateral spinal cord [24] could be
observed after ASA administration. Interestingly, nalox-
one did not invert the inhibitory effect on the brain
evoked potentials [24]. Furthermore, this effect was not
due to a peripheral blockade of inflammatory induced
neuropeptides [24], proposing a central inhibitory mech-
anism of action for ASA on the trigeminovascular
system [19,24]. Nonetheless, in the present study we
could not reveal a significant difference in BOLD signal
changes in response to trigeminal-nociceptive stimula-
tion in the trigeminal nuclei after ASA administration
compared to the saline condition. We note, that ASA
and triptans inhibit the nociceptive blink reflex in the
acute migraine attack, but seem to have no effect on tri-
geminal pain in migraineurs in the interictal state or in
healthy volunteers [42], suggesting a modulatory effect
on the trigeminal nociceptive system which occurs only
in the migraine attack but not in the healthy system nor
in the interictal phase [42], for example by blocking
sensitization.
In 1988 it was shown that administration of acetylsalicy-
late of lysine leads to an increase in 5-hydroxyindoleacetic
acid in the hypothalamus and the brainstem [43]. Investi-
gating the effect of aspirin on the inhibitory antinocicep-
tive brainstem reflex, another study obtained a significant
effect of ASA especially on the latency of the early sup-
pression period (ES1) within this exteroceptive suppres-
sion of electrical activity in the temporal muscle [44].
While ES1 latency was decreased in patients suffering
from a primary headache disease after administration of
ASA, it was increased in healthy participants [44]. More-
over, ASA caused a significant growth in ES2 (late sup-
pression period) duration [44], whereas placebo failed to
show this increase. An effect of ASA on complex pain
control mechanisms was suggested [44]. We did not find
any significant difference in BOLD signal changes in re-
sponse to trigeminal-nociceptive stimulation in the hypo-
thalamus of healthy volunteers after ASA administration
compared to saline condition. However, the dosage of
ASA used in the present study differs from earlier used
dosages [21]. Even though we chose to administer 500 mg
ASA (i.v.) because there is strong evidence showing itsclinical effectiveness in the acute migraine attack [1], the
divergence between dosages could at least partly explain
the obtained differences in neuronal activation. Finally,
ASA reveals its effect by inhibiting COX-1 and COX-2 en-
zymes that lead to the expression of prostaglandins which
play a crucial role within the inflammatory process [7,8]. It
is therefore to be expected that the effect of ASA is much
more pronounced in the state of hyperalgesia compared to
acute pain [21,26] and this could be another reason why
we did not find a significantly behavioral and only small
central modulatory effects of ASA on pain processing
structures.
Conclusion
Taken together, our study replicates earlier findings of a
possibly central effect of ASA on pain processing struc-
tures. As the model used in the present study allows to
investigate the central processing of trigeminal input
and it is well known that the trigeminal innervation
plays a pivotal role in the pain transmission of headache
disorders like migraine, our results support earlier indi-
cations that ASA might exert its therapeutic effect in
migraine through a combination of peripheral and cen-
tral mechanisms.
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